[go: up one dir, main page]

MX2021010668A - Proteinas de fusion de citoquinas. - Google Patents

Proteinas de fusion de citoquinas.

Info

Publication number
MX2021010668A
MX2021010668A MX2021010668A MX2021010668A MX2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A MX 2021010668 A MX2021010668 A MX 2021010668A
Authority
MX
Mexico
Prior art keywords
fusion proteins
cytokine fusion
nucleic acid
acid molecules
present
Prior art date
Application number
MX2021010668A
Other languages
English (en)
Inventor
Sebastian Kreiter
Ronald Backer
Roland Kontermann
Klaus Pfizenmaier
Dafne Müller
Ugur Sahin
Friederike Gieseke
Sina Fellermeier
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2021010668A publication Critical patent/MX2021010668A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona a proteínas de fusión de citoquinas y a moléculas de ácido nucleico que codifican dichas proteínas de fusión de citoquinas. La presente invención además se relaciona a las células, organismos no humanos, composiciones farmacéuticas y kits que incluyen proteínas de fusión de citoquinas o las moléculas de ácido nucleico que las codifican, así como a su utilización como medicamentos.
MX2021010668A 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas. MX2021010668A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/050682 WO2016112983A1 (en) 2015-01-15 2015-01-15 Cytokine fusion proteins

Publications (1)

Publication Number Publication Date
MX2021010668A true MX2021010668A (es) 2021-09-28

Family

ID=52394237

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009153A MX385926B (es) 2015-01-15 2016-01-15 Proteínas de fusión de citoquinas.
MX2021010668A MX2021010668A (es) 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009153A MX385926B (es) 2015-01-15 2016-01-15 Proteínas de fusión de citoquinas.

Country Status (11)

Country Link
US (2) US10301368B2 (es)
EP (1) EP3245223B1 (es)
JP (1) JP6813491B2 (es)
CN (2) CN113801241A (es)
AU (1) AU2016207955B2 (es)
BR (1) BR112017013956B1 (es)
CA (1) CA2971950C (es)
HK (1) HK1246316A1 (es)
MX (2) MX385926B (es)
NZ (1) NZ733266A (es)
WO (2) WO2016112983A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
WO2018132513A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation T cells experessing a chimeric antigen receptor
MY207687A (en) * 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
TW202428301A (zh) * 2017-02-28 2024-07-16 法商賽諾菲公司 治療性rna
AU2018247931B2 (en) 2017-04-06 2022-03-03 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
US11377490B2 (en) * 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
US11471490B2 (en) 2017-07-03 2022-10-18 Torque Therapeutics, Inc. T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
JP7566628B2 (ja) * 2018-01-10 2024-10-15 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現する免疫細胞
JP7676150B2 (ja) 2018-06-01 2025-05-14 サノフイ Ｂ型肝炎ウイルス感染を治療するための併用療法
IL282135B2 (en) * 2018-10-17 2025-06-01 Albert Einstein College Medicine Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc
CN113710702A (zh) * 2019-01-14 2021-11-26 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
EP3986920B1 (en) 2019-06-24 2025-04-16 Universität Stuttgart Tnfr2 agonists with improved stability
WO2021072127A2 (en) * 2019-10-08 2021-04-15 Fred Hutchinson Cancer Research Center Engineered trimeric cd70 proteins and uses thereof
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
HRP20150425T1 (hr) * 2008-07-21 2015-06-05 Apogenix Gmbh Tnf sf jednolanäśane molekule
CA2755198A1 (en) * 2009-03-13 2010-09-16 Mark L. Tykocinski Ox40/trail fusion proteins
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
WO2013159148A1 (en) * 2012-04-24 2013-10-31 Seafood Innovations Pty Ltd A fish corral and fish accumulator
PL2970427T3 (pl) * 2013-03-15 2020-06-01 Geoffrey W. STONE Kompozycja składająca się z antygenu związanego z ligandem z nadrodziny TNF

Also Published As

Publication number Publication date
US10808019B2 (en) 2020-10-20
MX2017009153A (es) 2018-02-01
BR112017013956A2 (pt) 2018-01-16
CN107428842A (zh) 2017-12-01
WO2016113395A1 (en) 2016-07-21
CN113801241A (zh) 2021-12-17
US20180002392A1 (en) 2018-01-04
HK1246315A1 (zh) 2018-09-07
BR112017013956A8 (pt) 2019-04-02
WO2016112983A1 (en) 2016-07-21
AU2016207955A1 (en) 2017-07-20
JP2018503379A (ja) 2018-02-08
EP3245223B1 (en) 2020-03-04
NZ733266A (en) 2022-04-29
US10301368B2 (en) 2019-05-28
HK1246316A1 (zh) 2018-09-07
CA2971950C (en) 2024-09-10
BR112017013956B8 (pt) 2024-01-23
BR112017013956B1 (pt) 2024-01-23
CA2971950A1 (en) 2016-07-21
CN107428842B (zh) 2021-10-01
JP6813491B2 (ja) 2021-01-13
EP3245223A1 (en) 2017-11-22
MX385926B (es) 2025-03-18
US20190276511A1 (en) 2019-09-12
AU2016207955B2 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2021010668A (es) Proteinas de fusion de citoquinas.
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
AU2017248555B2 (en) Closed nucleic acid structures
WO2015109124A3 (en) Immunomodulatory agents
MX2019000205A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
EP4501318A3 (en) Nucleic acid vaccines
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
GB2537077A (en) Methods for sequencing nucleic acids
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX384075B (es) Nuevas proteínas específicas para la angiogénesis.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
WO2016107818A8 (en) Compositions and methods for protein glycosylation
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
SG10201909180SA (en) Humanized anti-c1s antibodies and methods of use thereof
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EP4446410A3 (en) Compositions comprising polypeptides having galactanase activity and polypeptides having beta-galactosidase activity
BR112017025872A2 (pt) proteínas de ligação multiespecíficas